Adam Mullick

Arcturus Therapeutics, Inc. engages in the development of technology and therapeutics for rare diseases. It specializes in the application of application of ribonucleic acid technologies for the treatment of disease. The company was founded by Joseph E. Payne and Padmanabh Chivukula in 2013 and is headquartered in San Diego, CA.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Kent County Memorial Hospital provides health care services. It also provides inpatient services including cardiology and extended coronary care, infectious disease, primary care, oncology, orthopedics, obstetrics and gynecology, pediatrics, rehabilitation and surgery. The company was founded in 1951 and is headquartered in Warwick, RI.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

St. Thomas Hospital, Inc. operates hospitals. The private company is based in St. Thomas, VI. and has subsidiaries in United States.

Nitto Denko Technical Corp. focuses on cutting edge technologies that will provide practical solutions for Pharmaceutical, Drug Delivery, Medical, Electric, Environmental, Optronics, Nanoceramics and Nanoorganics. The Company was founded in October 2000 and is headquartered in Oceanside, CA.

DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA.

Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA.

Claris Ventures Sgr SpA (Claris Ventures) is a venture capital firm founded in 2019 by Pietro Puglisi and Ciro Spedaliere. The firm is headquartered in Turin, Italy.

Adjuvant Capital LP (Adjuvant Capital) is a private equity and venture capital firm founded in 2018 by Glenn Rockman, Kabeer Aziz and Charlie Petty. The firm is headquartered in New York.

Resalis Therapeutics SRL is a company that focuses on developing a transformative metabolic disease approach to target obesity and fatty liver disease. The company is based in Turin, Italy. The Italian company's lead program, RES-010, is a safe and convenient treatment that provides disease-modifying therapeutic impact, including durable weight loss and reduction of hepatic steatosis. The CEO of the company is Eva Castagnetti.